Kuan-Ju Lee

Kuan-Ju Lee

Auto-generated profile, based on publicly available information

Kuan-Ju Lee

Department of General Surgery and Breast surgery, Chang Gung Memorial Hospital Linkou branch, Taoyuan 33305, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Translational Oncology
Verified
Journal Article
Open access
HCHsu-Huan Chou
Hsu-Huan Chou
TCTing-Fang Che
Ting-Fang Che
KLKuan-Ju Lee
Kuan-Ju Lee
SCShin-Cheh Chen
Shin-Cheh Chen
JCJia-Yang Chen
Jia-Yang Chen
CTChi-Neu Tsai
Chi-Neu Tsai
Tumor heterogeneity and drug resistance remain key challenges in breast cancer management. While organoid cultures can be established from resected tumor specimens, patients undergoing systematic treatment often lack accessible tissue for ex vivo drug testing. Circulating tumor cells (CTCs) offer a minimally invasive alternative. The purpose of this study was to establish a clinically feasible workflow that integrates CTC enumeration and CTC-derived spheroid drug screening to overcome the limitations of tissue-dependent organoid models and enable personalized treatment in breast cancer. CTCs were isolated from 34 newly diagnosed breast cancer patients using a liposome-tethered supported lipid bilayer (LIPO-SLB) microfluidic platform functionalized with anti-EpCAM antibodies. Thirteen patients undergoing systemic therapy and relapse were further assessed using CTC-spheroid culture for ex vivo drug screening. Hormone receptor expression and genomic mutation profiles were integrated with drug testing. One relapsed case underwent pre- and post-treatment spatial transcriptomic analysis (Xenium in situ). CTC and CTC-cluster counts significantly declined post-treatment in responders (p=0.044 and p=0.0264, respectively), but not in non-responders. CTC-spheroids were successfully generated in all 13 cases, enabling ex vivo drug testing. Effective therapies were identified in 9 patients (69.2%), of whom 7 achieved partial responses and 1 achieved stable disease; one patient did not receive the suggested treatment. Ex vivo drug sensitivity results correlated with clinical outcomes. Integrating CTC-based drug testing, hormone receptor expression in CTCs, and genomic DNA mutation profile further improved prediction of radiological response. Spatial transcriptomics revealed therapy-induced clonal shifts, with resistant subpopulations characterized by over-expression of chemoresistant gene, EIF4EBP1. This study demonstrates that CTC-derived spheroid drug screening provides actionable therapeutic guidance when tissue is unavailable. Combined with hormone receptor and genomic profiling, this liquid biopsy-based platform enables personalized treatment, and dynamic monitoring of resistance in breast cancer.